Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
Formule empirique (notation de Hill) :
C14H15ClN2OS
Numéro CAS:
Poids moléculaire :
294.80
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderInChI
1S/C14H15ClN2OS/c1-9(2)12(10-3-5-11(15)6-4-10)13(18)17-14-16-7-8-19-14/h3-9,12H,1-2H3,(H,16,17,18)
SMILES string
CC(C)C(C(=O)Nc1nccs1)c2ccc(Cl)cc2
InChI key
AZYDQCGCBQYFSE-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
Application
4-CMTB has been used as an allosteric agonist for the free fatty acid receptor 2 (FFAR2) in human lung carcinoma (A549) cells for cell viability assay and Influenza A virus (IAV) internalization studies.
Biochem/physiol Actions
4-CMTB is a phenylacetamide compound that acts as an allosteric modulator for the activity of short-chain fatty acid ligand in the FFA2 receptor.
4-CMTB is a potent allosteric agonist of FFA2.
4-CMTB is a potent allosteric agonist of free fatty acid receptor 2 (FFA2).
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Nicola J Smith et al.
Molecular pharmacology, 80(1), 163-173 (2011-04-19)
Allosteric agonists are powerful tools for exploring the pharmacology of closely related G protein-coupled receptors that have nonselective endogenous ligands, such as the short chain fatty acids at free fatty acid receptors 2 and 3 (FFA2/GPR43 and FFA3/GPR41, respectively). We
Sandra Rutting et al.
American journal of physiology. Lung cellular and molecular physiology, 316(1), L157-L174 (2018-11-09)
Short-chain fatty acids (SCFAs), produced as by-products of dietary fiber metabolism by gut bacteria, have anti-inflammatory properties and could potentially be used for the treatment of inflammatory diseases, including asthma. The direct effects of SCFAs on inflammatory responses in primary
Ludovica Marinelli et al.
Scientific reports, 9(1), 643-643 (2019-01-27)
The ligand activated transcription factor, aryl hydrocarbon receptor (AhR) emerged as a critical regulator of immune and metabolic processes in the gastrointestinal tract. In the gut, a main source of AhR ligands derives from commensal bacteria. However, many of the
Sarah Ducastel et al.
Scientific reports, 10(1), 174-174 (2020-01-15)
The gut microbiota participates in the control of energy homeostasis partly through fermentation of dietary fibers hence producing short-chain fatty acids (SCFAs), which in turn promote the secretion of the incretin Glucagon-Like Peptide-1 (GLP-1) by binding to the SCFA receptors
Matilda Shackley et al.
Frontiers in nutrition, 7, 568991-568991 (2020-11-17)
The short chain fatty acids (SCFAs) acetate, butyrate and propionate, are produced by fermentation of non-digestible carbohydrates by the gut microbiota and regulate appetite, adiposity, metabolism, glycemic control, and immunity. SCFAs act at two distinct G protein coupled receptors (GPCRs)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique